Merck Unveils New Data at European Society of Cardiology Congress 2025

Merck will present new research data at the European Society of Cardiology Congress 2025, focusing on atherosclerotic cardiovascular disease, pulmonary hypertension, and heart failure with reduced ejection fraction. Key presentations include real-world studies and clinical trials, with a focus on treatments such as WINREVAIR (sotatercept-csrk) and VERQUVO (vericiguat).

Merck (NYSE: MRK), a leading pharmaceutical company, will present new clinical trial and outcomes research data at the European Society of Cardiology Congress (ESC) 2025 in Madrid from August 29 to September 1. The focus will be on atherosclerotic cardiovascular disease (ASCVD), pulmonary hypertension (PH), and heart failure with reduced ejection fraction (HFrEF). Key presentations include real-world studies and clinical trials, with a particular emphasis on treatments such as WINREVAIR (sotatercept-csrk) and VERQUVO (vericiguat).

The company will share two oral presentations on ASCVD, evaluating the clinical and economic burden on patients with and without myocardial infarction using a 10-year registry, and exploring temporal trends in lipid-lowering therapy utilization in a large-scale patient population with ASCVD [1]. Additionally, details on Merck's clinical trial research for WINREVAIR in PH, including the rationale and design of the CADENCE trial, will be presented [1]. Results from the ZENITH trial, which assesses the effect of WINREVAIR on hemodynamics in high-risk pulmonary arterial hypertension (PAH), will also be shared.

Merck will present data from the VICTOR trial and a pooled-analysis of the VICTOR and VICTORIA trials, along with real-world analyses, evaluating VERQUVO in adult patients with HFrEF [1]. The company will also host three symposia throughout the congress, focusing on hyperlipidemia management, treating PAH by reverse remodeling, and barriers and challenges in cardiovascular disease (CVD) [1].

InvestingPro analysis indicates that Merck maintains a strong financial health score of "GREAT," supporting its robust research initiatives [2]. This presentation underscores Merck's ongoing commitment to advancing cardiovascular research and improving patient outcomes globally.

References:
[1] https://www.nasdaq.com/press-release/merck-demonstrates-ongoing-commitment-advancing-cardiovascular-disease-management-and
[2] https://www.investing.com/news/company-news/merck-to-present-new-cardiovascular-disease-data-at-esc-2025-93CH-4208621